GlassScriptPhysician profile
Sheikh Ahmed
NPI 1457435745
$13,732.26
in general payments reported to CMS, 2019-2025
24 companies · $399 in 2025
The $399 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $208 · 2021: $11K · 2022: $721 · 2023: $792 · 2024: $441 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,612 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,611.79 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $9,826.60 | 2021 | |
| Abbott Laboratories | $1,986.52 | 2019-2025 | Confirm Rx, Gallant |
| Amgen INC. | $283.87 | 2019-2025 | Evenity, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $247.22 | 2021-2025 | |
| Lilly USA, LLC | $242.39 | 2022-2025 | Mounjaro, Jardiance, Kisunla |
| Merck Sharp & Dohme LLC | $208.94 | 2020-2023 | Verquvo, Steglatro, Steglujan |
| E.R. Squibb & Sons, L.L.C. | $149.84 | 2022-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $133.10 | 2022-2023 | Xarelto |
| Biotronik INC. | $122.79 | 2019-2021 | |
| Radius Health, INC. | $103.61 | 2023-2025 | Tymlos |
| Glaxosmithkline, LLC. | $75.98 | 2023-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $65.82 | 2020-2025 | Farxiga |
| Boston Scientific Corporation | $46.35 | 2022 | |
| Novartis Pharmaceuticals Corporation | $43.25 | 2019-2023 | |
| Pfizer INC. | $27.94 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $27.40 | 2024 | |
| Verona Pharma, INC. | $25.23 | 2025 | Ohtuvayre |
| Scpharmaceuticals INC. | $19.88 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.91 | 2019 | |
| Sumitomo Pharma America, INC. | $18.25 | 2023 | Gemtesa |
| Agepha Pharma Fz LLC | $16.12 | 2024 | Lodoco |
| Esperion Therapeutics, INC. | $14.96 | 2024 | Nexletol |
| Abbvie INC. | $14.63 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheikh Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.